Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN On-line: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i2.30
pages 161-173

Targeting the Insulin-like Growth Factor Receptor: Developing Biomarkers from Gene Expression Profiling

David N. Boone
Women's Cancer Research Center and Department of Pharmacology & Chemical Biology, University of Pittsburgh Cancer Institute, Magee Womens Research Institute
Adrian V. Lee
Women's Cancer Research Center and Department of Pharmacology & Chemical Biology, University of Pittsburgh Cancer Institute, Magee Womens Research Institute

RESUMO

Overwhelming evidence implicates insulin-like growth factor (IGF) signaling in the growth and survival of many types of human cancer cells. Numerous inhibitors of the IGF1 receptor (IGF1R) have been developed, and they displayed remarkable antineoplastic activity in preclinical models and promising success in early phase clinical trials. However, while responses have been observed in numerous cancer types, they have occurred in a minority of patients, and serious toxicities have been observed. Identifying patients likely to benefit from anti-IGF1R therapy requires further characterizing the role of IGF1 signaling in various stages of tumorigenesis in order to identify critical downstream factors that may be used as predictors of response, or to serve as novel therapeutic targets. Recent microarray analyses have begun to unravel expression "signatures" specific for IGF1 that correlate with poor breast cancer prognosis and with response to anti-IGFIR inhibitors. In this review we briefly discuss the history of the IGF1 family in neoplasia, how it is targeted, results from clinical trials, and the quest for biomarkers that will predict response to IGF1R-targeted therapy.


Articles with similar content:

Predictive Biomarkers for Response to Therapy in Advanced Colorectal/Rectal Adenocarcinoma
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 4
Payal Kapur
CREB and Leukemogenesis
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 1-2
Bryan Mitton, Er-Chieh Cho, Kathleen Sakamoto
Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Wenwen Guo, Xue He, Congyang Wang, Nannan Chen, Yan Wang, Fengxia He, Li Lin
KLF4 in Ovarian Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Lawrence M. Pfeffer, Baojin Wang, Ziyun Du, Junming Yue
Current Status of Radiosensitizing Agents for the Management of Rectal Cancer
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 4
Henrik Illum